Before match | After match | |||||
---|---|---|---|---|---|---|
ATT (n = 30) | Non-ATT (n = 120) | P value | ATT (n = 22) | Non-ATT (n = 22) | P value | |
Age | 77 (44–90) | 70 (25–100) | 0.065 | 77 (59–90) | 72 (51–92) | 0.549 |
Sex (Male/Female) | 23/7 | 70/50 | 0.092 | 15/7 | 15/7 | 1.000 |
BMI (kg/m2) | 23.1 (3.9) | 23.9 (3.8) | 0.302 | 22.5 (3.4) | 22.4 (3.1) | 0.973 |
ASA-PS (1,2/3,4) | 16/14 | 105/15 | < 0.001 | 14/8 | 17/5 | 0.510 |
CCI | 1 (0–6) | 0 (0–4) | 0.001 | 1 (0–6) | 1 (0–4) | 0.714 |
TG18 grade (1/2,3) | 8/22 | 78/42 | < 0.001 | 8/14 | 10/12 | 0.760 |
WBC (104/µL) | 1.5 (0.5) | 1.3 (0.5) | 0.039 | 1.3 (0.5) | 1.5 (0.4) | 0.489 |
Hb (g/dL) | 12.7 (1.7) | 13.6 (2.0) | 0.028 | 12.7 (1.4) | 12.7 (2.4) | 0.970 |
Plt (104/µL) | 21.0 (7.5) | 23.2 (8.1) | 0.180 | 21.5 (8.1) | 23.1 (7.1) | 0.489 |
CRP (mg/dL) | 14.8 (0.1–44.1) | 4.0 (0.0–18.4) | 0.004 | 15.8 (0.1–44.1) | 2.4 (0.0–30.9) | 0.022 |
Alb (g/dL) | 3.4 (0.7) | 3.7 (0.7) | 0.007 | 3.4 (0.7) | 3.7 (0.8) | 0.190 |
Total bilirubin (mg/dL) | 1.2 (0.2–5.4) | 1.0 (0.2–16.8) | 0.195 | 1.1 (0.2–5.4) | 0.9 (0.4–10.3) | 0.597 |
AST | 25 (14–513) | 24 (11–1243) | 0.842 | 24 (14–201) | 23 (11–390) | 0.787 |
ALT | 19 (6–515) | 24 (6–866) | 0.491 | 17 (6–114) | 20 (6–866) | 0.526 |
ALP | 273 (155–1369) | 258 (115–1477) | 0.521 | 256 (155–627) | 270 (121–1477) | 0.771 |
γGTP (IU/L) | 50 (9–450) | 40 (12–572) | 0.932 | 47 (9–128) | 43 (14–572) | 0.488 |
Cr | 0.8 (0.4–7.3) | 0.8 (0.3–7.1) | 0.116 | 0.8 (0.5–7.3) | 0.8 (0.5–7.1) | 0.953 |
PT-INR | 1.2 (1.0–2.0) | 1.1 (0.9–1.4) | < 0.001 | 1.2 (1.0–1.6) | 1.0 (0.9–1.3) | 0.001 |
APTT (s) | 41.1 (26.6–76.1) | 33.5 (21.4–53.6) | < 0.001 | |||
ACT (%) | 7 (23.3) | 4 (18.2) | ||||
APT (%) | 25 (83.3) | 18 (81.8) | ||||
Multiple dosage (%)a | 5 (16.7) | 2 (9/1) | ||||
Duration until operation from onset | 3 (1–10) | 2 (1–30) | 0.088 | 3 (1–10) | 3 (1–10) | 0.157 |